In 2022,gastric cancer(GC)ranked as the fifth most common cancer and the third leading cause of cancer death in China,with 358,672 new cases and 260,372 deaths,accounting for 37.0%and 39.4%of global cases,respectively...In 2022,gastric cancer(GC)ranked as the fifth most common cancer and the third leading cause of cancer death in China,with 358,672 new cases and 260,372 deaths,accounting for 37.0%and 39.4%of global cases,respectively[1].Previous studies have shown that 25.9%and 36.5%of GC patients in China were diagnosed at stages III and IV,respectively,with 5-year overall survival(OS)rates of 33.0%for stage III and 5.5%for stage IV[2,3].展开更多
基金approved by the Independent Ethics Committee of Chinese PLA General Hospital(C2021-102-01)Changzhi People’s Hospital(LSPJ2022006)+17 种基金Fujian Provincial Cancer Hospital(2022-016-01)Cancer Hospital of Shandong First Medical University(SDZLEC2022-042-01)The First People’s Hospital of Changde City(2022-016-01)Jilin Cancer Hospital(202201-011-01)Linyi People’s Hospital(2022-lunlishencha-10)Liaoning Cancer Hospital and Institute(20220205)Shanxi Province Cancer Hospital(YW2022009)Affiliated Cancer Hospital of Zhengzhou University,Henan Cancer Hospital(L2022-Y010-002)Harbin Medical University Cancer Hospital(2022-91)Anhui Provincial Cancer Hospital,The First Affiliated Hospital of University of Science and Technology of China(2022-lunlishencha-08)The Fourth Hospital of Hebei Medical University(2022044)Binzhou Medical University Hospital(2022-001-01)Central Hospital Affiliated to Shandong Medical University(jizhongxinlunlilinshen2022-011-01)Qingdao Central Hospital,University of Health and Rehabilitation Science([Y]SY202200401)Liaocheng People’s Hospital(2022006)Suining Central Hospital(2022-lunliyijian-sy002-01)Yanan University Xianyang Hospital(YDXYEC-YWPJ-2022-5)conducted in accordance with the Declaration of Helsinki and Good Clinical Practices.Written informed consent was obtained from all patients before enrollment.
文摘In 2022,gastric cancer(GC)ranked as the fifth most common cancer and the third leading cause of cancer death in China,with 358,672 new cases and 260,372 deaths,accounting for 37.0%and 39.4%of global cases,respectively[1].Previous studies have shown that 25.9%and 36.5%of GC patients in China were diagnosed at stages III and IV,respectively,with 5-year overall survival(OS)rates of 33.0%for stage III and 5.5%for stage IV[2,3].
